Literature DB >> 29147358

Excellent Response to Palliative Chemotherapy for Pleural Recurrence of Uterine Papillary Serous Carcinoma.

Shantanu Singh1, David Mack1, Dianne Dookhan1, Juthika Jyotimallika1.   

Abstract

Uterine papillary serous carcinoma (UPSC) is an aggressive variant of endometrial cancer. Though the majority of women with UPSC have high risk of recurrence, recurrence limited only to the pleural space has not been previously reported. It is also unusual for it to occur as late as 10 years after the initial treatment as it is usually very aggressive. There is scant information in literature on response to treatment in these patients. A 65-year-old African-American woman was treated for FIGO stage IIA UPSC with total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymphadenectomy with 32P catheter placement, followed by adjuvant external beam radiation. She relapsed 10 years later with right pleural effusion and pleural based nodules. Fluid cytology was consistent with UPSC. She was treated with 6 cycles of carboplatin and paclitaxel with excellent clinical and biochemical response. She continues to remain disease free 5 years later. To our knowledge, this is the first reported case of UPSC recurrence limited to pleura, and this is also the first reported case of UPSC recurrence without evidence of disease 5 years after palliative chemotherapy.

Entities:  

Keywords:  Chemotherapy; Pleural fluid cytology; Pleural recurrence; Uterine papillary serous carcinoma

Year:  2013        PMID: 29147358      PMCID: PMC5649930          DOI: 10.4021/wjon704w

Source DB:  PubMed          Journal:  World J Oncol        ISSN: 1920-4531


  14 in total

1.  Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  G Plataniotis; M Castiglione
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Tubal (serous) carcinoma of the endometrium.

Authors:  S C Lauchlan
Journal:  Arch Pathol Lab Med       Date:  1981-11       Impact factor: 5.534

3.  Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.

Authors:  Angiolo Gadducci; Stefania Cosio; Fabio Landoni; Tiziano Maggino; Paolo Zola; Luca Fuso; Enrico Sartori
Journal:  Int J Gynecol Cancer       Date:  2012-10       Impact factor: 3.437

4.  Patterns of pulmonary metastasis from uterine cancer.

Authors:  D Bouros; K Papadakis; N Siafakas; A F Fuller
Journal:  Oncology       Date:  1996 Sep-Oct       Impact factor: 2.935

5.  Outcomes in surgical stage I uterine papillary serous carcinoma.

Authors:  Laura J Havrilesky; Angeles Alvarez Secord; Victoria Bae-Jump; Tina Ayeni; Brian Calingaert; Daniel L Clarke-Pearson; Andrew Berchuck; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2007-03-13       Impact factor: 5.482

Review 6.  Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.

Authors:  David M Boruta; Paola A Gehrig; Amanda Nickles Fader; Alexander B Olawaiye
Journal:  Gynecol Oncol       Date:  2009-07-09       Impact factor: 5.482

7.  Two pathogenetic types of endometrial carcinoma.

Authors:  J V Bokhman
Journal:  Gynecol Oncol       Date:  1983-02       Impact factor: 5.482

8.  Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.

Authors:  Alexander B Olawaiye; Jose Alejandro Rauh-Hain; Matthew Withiam-Leitch; Bo Rueda; Annekathryn Goodman; Marcela G del Carmen
Journal:  Gynecol Oncol       Date:  2008-07-21       Impact factor: 5.482

9.  Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.

Authors:  Brij M Sood; Joan Jones; Sajel Gupta; Dineo Khabele; Chandan Guha; Carol Runowicz; Gary Goldberg; Abbie Fields; Patrick Anderson; B Vikram
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-09-01       Impact factor: 7.038

10.  Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors.

Authors:  Gloria S Huang; Juliana S Gebb; Mark H Einstein; Shohreh Shahabi; Akiva P Novetsky; Gary L Goldberg
Journal:  Am J Obstet Gynecol       Date:  2007-03       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.